![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BAYER SPINS OFF ANTI-INFECTIVES UNIT INTO CO IN WHICH SANTO HOLDS MAJORITY STAKE
BAYER SPINS OFF ANTI-INFECTIVES UNIT INTO CO IN WHICH SANTO HOLDS MAJORITY STAKE
November 3, 2005
Bayer AG said it plans to spin off its anti-infectives research unit into a
new company in which Stuttgart-based Santo Holding Deutschland AG will own a
majority holding. Bayer will retain a minority holding. The transaction will
be completed in the first quarter of 2006. No financial details were disclosed.
The research fields covered by the unit include human cytomegalovirus, hepatitis
C, HIV, herpes and gram-positive bacteria.
Forbes
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct